Efficacy and safety of ideglira in older patients with type 2 diabetes

Ildiko Lingvay, Yehuda Handelsman, Sultan Linjawi, Tina Vilsbøll, Natalie Halladin, Kristina Ranc, Andreas Liebl

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The efficacy and safety of insulin degludec/ liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years. Methods: A post hoc analysis compared results of patients aged ≥65 versus <;65 years from DUAL II, III, and V. These were 26-week, phase 3, randomized, two-arm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents. We evaluated 311 patients aged <;65 and 87 patients aged ≥65 years from DUAL II, 326 patients <;65 years and 112 patients ≥65 years from DUAL III, and 412 patients <;65 years and 145 patients ≥65 years from DUAL V. Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V). Results: In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, −1.0% [−1.5; −0.6] 95% confidence interval [CI], −0.8% [−1.0; −0.5] 95% CI, and −0.9% [−1.3; −0.6] 95%CI ) for DUAL II, V, and III, respectively; all P<;.001). These mirrored results of patients <;65 years of age. Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6] 95% CI [P = .242]; 0.3 [0.1; 0.5] 95% CI [P<;.001], and 11.8 [3.3; 42.8] 95% CI [P<;.001] for DUAL II, V, and III, respectively). Conclusion: Patients aged ≥65 years on basal insulin or GLP-1RA can improve glycemic control with IDegLira, and it is well tolerated overall.

Original languageEnglish (US)
Pages (from-to)144-155
Number of pages12
JournalEndocrine Practice
Volume25
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Type 2 Diabetes Mellitus
Safety
Confidence Intervals
Insulin
insulin degludec
Liraglutide
Hypoglycemia
Hemoglobins

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Lingvay, I., Handelsman, Y., Linjawi, S., Vilsbøll, T., Halladin, N., Ranc, K., & Liebl, A. (2019). Efficacy and safety of ideglira in older patients with type 2 diabetes. Endocrine Practice, 25(2), 144-155. https://doi.org/10.4158/EP-2018-0284

Efficacy and safety of ideglira in older patients with type 2 diabetes. / Lingvay, Ildiko; Handelsman, Yehuda; Linjawi, Sultan; Vilsbøll, Tina; Halladin, Natalie; Ranc, Kristina; Liebl, Andreas.

In: Endocrine Practice, Vol. 25, No. 2, 01.02.2019, p. 144-155.

Research output: Contribution to journalArticle

Lingvay, I, Handelsman, Y, Linjawi, S, Vilsbøll, T, Halladin, N, Ranc, K & Liebl, A 2019, 'Efficacy and safety of ideglira in older patients with type 2 diabetes', Endocrine Practice, vol. 25, no. 2, pp. 144-155. https://doi.org/10.4158/EP-2018-0284
Lingvay I, Handelsman Y, Linjawi S, Vilsbøll T, Halladin N, Ranc K et al. Efficacy and safety of ideglira in older patients with type 2 diabetes. Endocrine Practice. 2019 Feb 1;25(2):144-155. https://doi.org/10.4158/EP-2018-0284
Lingvay, Ildiko ; Handelsman, Yehuda ; Linjawi, Sultan ; Vilsbøll, Tina ; Halladin, Natalie ; Ranc, Kristina ; Liebl, Andreas. / Efficacy and safety of ideglira in older patients with type 2 diabetes. In: Endocrine Practice. 2019 ; Vol. 25, No. 2. pp. 144-155.
@article{07c3e950178049d38637d80c13a94786,
title = "Efficacy and safety of ideglira in older patients with type 2 diabetes",
abstract = "Objective: The efficacy and safety of insulin degludec/ liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years. Methods: A post hoc analysis compared results of patients aged ≥65 versus <;65 years from DUAL II, III, and V. These were 26-week, phase 3, randomized, two-arm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents. We evaluated 311 patients aged <;65 and 87 patients aged ≥65 years from DUAL II, 326 patients <;65 years and 112 patients ≥65 years from DUAL III, and 412 patients <;65 years and 145 patients ≥65 years from DUAL V. Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V). Results: In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, −1.0{\%} [−1.5; −0.6] 95{\%} confidence interval [CI], −0.8{\%} [−1.0; −0.5] 95{\%} CI, and −0.9{\%} [−1.3; −0.6] 95{\%}CI ) for DUAL II, V, and III, respectively; all P<;.001). These mirrored results of patients <;65 years of age. Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6] 95{\%} CI [P = .242]; 0.3 [0.1; 0.5] 95{\%} CI [P<;.001], and 11.8 [3.3; 42.8] 95{\%} CI [P<;.001] for DUAL II, V, and III, respectively). Conclusion: Patients aged ≥65 years on basal insulin or GLP-1RA can improve glycemic control with IDegLira, and it is well tolerated overall.",
author = "Ildiko Lingvay and Yehuda Handelsman and Sultan Linjawi and Tina Vilsb{\o}ll and Natalie Halladin and Kristina Ranc and Andreas Liebl",
year = "2019",
month = "2",
day = "1",
doi = "10.4158/EP-2018-0284",
language = "English (US)",
volume = "25",
pages = "144--155",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of ideglira in older patients with type 2 diabetes

AU - Lingvay, Ildiko

AU - Handelsman, Yehuda

AU - Linjawi, Sultan

AU - Vilsbøll, Tina

AU - Halladin, Natalie

AU - Ranc, Kristina

AU - Liebl, Andreas

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objective: The efficacy and safety of insulin degludec/ liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years. Methods: A post hoc analysis compared results of patients aged ≥65 versus <;65 years from DUAL II, III, and V. These were 26-week, phase 3, randomized, two-arm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents. We evaluated 311 patients aged <;65 and 87 patients aged ≥65 years from DUAL II, 326 patients <;65 years and 112 patients ≥65 years from DUAL III, and 412 patients <;65 years and 145 patients ≥65 years from DUAL V. Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V). Results: In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, −1.0% [−1.5; −0.6] 95% confidence interval [CI], −0.8% [−1.0; −0.5] 95% CI, and −0.9% [−1.3; −0.6] 95%CI ) for DUAL II, V, and III, respectively; all P<;.001). These mirrored results of patients <;65 years of age. Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6] 95% CI [P = .242]; 0.3 [0.1; 0.5] 95% CI [P<;.001], and 11.8 [3.3; 42.8] 95% CI [P<;.001] for DUAL II, V, and III, respectively). Conclusion: Patients aged ≥65 years on basal insulin or GLP-1RA can improve glycemic control with IDegLira, and it is well tolerated overall.

AB - Objective: The efficacy and safety of insulin degludec/ liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years. Methods: A post hoc analysis compared results of patients aged ≥65 versus <;65 years from DUAL II, III, and V. These were 26-week, phase 3, randomized, two-arm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents. We evaluated 311 patients aged <;65 and 87 patients aged ≥65 years from DUAL II, 326 patients <;65 years and 112 patients ≥65 years from DUAL III, and 412 patients <;65 years and 145 patients ≥65 years from DUAL V. Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V). Results: In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, −1.0% [−1.5; −0.6] 95% confidence interval [CI], −0.8% [−1.0; −0.5] 95% CI, and −0.9% [−1.3; −0.6] 95%CI ) for DUAL II, V, and III, respectively; all P<;.001). These mirrored results of patients <;65 years of age. Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6] 95% CI [P = .242]; 0.3 [0.1; 0.5] 95% CI [P<;.001], and 11.8 [3.3; 42.8] 95% CI [P<;.001] for DUAL II, V, and III, respectively). Conclusion: Patients aged ≥65 years on basal insulin or GLP-1RA can improve glycemic control with IDegLira, and it is well tolerated overall.

UR - http://www.scopus.com/inward/record.url?scp=85062431060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062431060&partnerID=8YFLogxK

U2 - 10.4158/EP-2018-0284

DO - 10.4158/EP-2018-0284

M3 - Article

C2 - 30383495

AN - SCOPUS:85062431060

VL - 25

SP - 144

EP - 155

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 2

ER -